

**PHARMACIST PRESCRIPTION AUTHORITY AMENDMENTS**

2018 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Todd Weiler**

House Sponsor: \_\_\_\_\_

---

---

**LONG TITLE**

**General Description:**

This bill permits a pharmacist to prescribe and dispense a self-administered hormonal contraceptive.

**Highlighted Provisions:**

This bill:

- ▶ expands the definition of the practice of pharmacy to include prescribing and dispensing a self-administered hormonal contraceptive; and
- ▶ creates standards and procedures that a pharmacist must follow when prescribing a self-administered hormonal contraceptive.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**

None

**Utah Code Sections Affected:**

AMENDS:

**58-17b-102**, as last amended by Laws of Utah 2015, Chapter 336

**58-17b-501**, as last amended by Laws of Utah 2017, Chapter 392

**58-17b-502**, as last amended by Laws of Utah 2016, Chapter 405

ENACTS:

**58-17b-626**, Utah Code Annotated 1953



28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

---

---

*Be it enacted by the Legislature of the state of Utah:*

Section 1. Section **58-17b-102** is amended to read:

**58-17b-102. Definitions.**

In addition to the definitions in Section [58-1-102](#), as used in this chapter:

(1) "Administering" means:

(a) the direct application of a prescription drug or device, whether by injection, inhalation, ingestion, or by any other means, to the body of a human patient or research subject by another person; or

(b) the placement by a veterinarian with the owner or caretaker of an animal or group of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other means directed to the body of the animal by the owner or caretaker in accordance with written or verbal directions of the veterinarian.

(2) "Adulterated drug or device" means a drug or device considered adulterated under 21 U.S.C. Sec. 351 (2003).

(3) (a) "Analytical laboratory" means a facility in possession of prescription drugs for the purpose of analysis.

(b) "Analytical laboratory" does not include a laboratory possessing prescription drugs used as standards and controls in performing drug monitoring or drug screening analysis if the prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid components, organic solvents, or inorganic buffers at a concentration not exceeding one milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic use.

(4) "Animal euthanasia agency" means an agency performing euthanasia on animals by the use of prescription drugs.

(5) "Automated pharmacy systems" includes mechanical systems which perform operations or activities, other than compounding or administration, relative to the storage, packaging, dispensing, or distribution of medications, and which collect, control, and maintain all transaction information.

(6) "Beyond use date" means the date determined by a pharmacist and placed on a prescription label at the time of dispensing that indicates to the patient or caregiver a time

59 beyond which the contents of the prescription are not recommended to be used.

60 (7) "Board of pharmacy" or "board" means the Utah State Board of Pharmacy created  
61 in Section [58-17b-201](#).

62 (8) "Branch pharmacy" means a pharmacy or other facility in a rural or medically  
63 underserved area, used for the storage and dispensing of prescription drugs, which is dependent  
64 upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and  
65 approved by the division as the parent pharmacy.

66 (9) "Centralized prescription processing" means the processing by a pharmacy of a  
67 request from another pharmacy to fill or refill a prescription drug order or to perform  
68 processing functions such as dispensing, drug utilization review, claims adjudication, refill  
69 authorizations, and therapeutic interventions.

70 (10) "Class A pharmacy" means a pharmacy located in Utah that is authorized as a  
71 retail pharmacy to compound or dispense a drug or dispense a device to the public under a  
72 prescription order.

73 (11) "Class B pharmacy":

74 (a) means a pharmacy located in Utah:

75 (i) that is authorized to provide pharmaceutical care for patients in an institutional  
76 setting; and

77 (ii) whose primary purpose is to provide a physical environment for patients to obtain  
78 health care services; and

79 (b) (i) includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and

80 (ii) pharmaceutical administration and sterile product preparation facilities.

81 (12) "Class C pharmacy" means a pharmacy that engages in the manufacture,  
82 production, wholesale, or distribution of drugs or devices in Utah.

83 (13) "Class D pharmacy" means a nonresident pharmacy.

84 (14) "Class E pharmacy" means all other pharmacies.

85 (15) "Closed-door pharmacy" means a pharmacy that provides pharmaceutical care to a  
86 defined and exclusive group of patients who have access to the services of the pharmacy  
87 because they are treated by or have an affiliation with a specific entity, including a health  
88 maintenance organization or an infusion company, but not including a hospital pharmacy, a  
89 retailer of goods to the general public, or the office of a practitioner.

90 (16) "Collaborative pharmacy practice" means a practice of pharmacy whereby one or  
91 more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or  
92 more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical  
93 care functions authorized by the practitioner or practitioners under certain specified conditions  
94 or limitations.

95 (17) "Collaborative pharmacy practice agreement" means a written and signed  
96 agreement between one or more pharmacists and one or more practitioners that provides for  
97 collaborative pharmacy practice for the purpose of drug therapy management of patients and  
98 prevention of disease of human subjects.

99 (18) (a) "Compounding" means the preparation, mixing, assembling, packaging, or  
100 labeling of a limited quantity drug, sterile product, or device:

101 (i) as the result of a practitioner's prescription order or initiative based on the  
102 practitioner, patient, or pharmacist relationship in the course of professional practice;

103 (ii) for the purpose of, or as an incident to, research, teaching, or chemical analysis and  
104 not for sale or dispensing; or

105 (iii) in anticipation of prescription drug orders based on routine, regularly observed  
106 prescribing patterns.

107 (b) "Compounding" does not include:

108 (i) the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to  
109 another pharmacist or pharmaceutical facility;

110 (ii) the preparation by a pharmacist or pharmacy intern of any prescription drug in a  
111 dosage form which is regularly and commonly available from a manufacturer in quantities and  
112 strengths prescribed by a practitioner; or

113 (iii) the preparation of a prescription drug, sterile product, or device which has been  
114 withdrawn from the market for safety reasons.

115 (19) "Confidential information" has the same meaning as "protected health  
116 information" under the Standards for Privacy of Individually Identifiable Health Information,  
117 45 C.F.R. Parts 160 and 164.

118 (20) "Controlled substance" means the same as that term is defined in Section [58-37-2](#).

119 (21) "Dietary supplement" has the same meaning as Public Law Title 103, Chapter  
120 417, Sec. 3a(ff) which is incorporated by reference.

121 (22) "Dispense" means the interpretation, evaluation, and implementation of a  
122 prescription drug order or device or nonprescription drug or device under a lawful order of a  
123 practitioner in a suitable container appropriately labeled for subsequent administration to or use  
124 by a patient, research subject, or an animal.

125 (23) "Dispensing medical practitioner" means an individual who is:

126 (a) currently licensed as:

127 (i) a physician and surgeon under Chapter 67, Utah Medical Practice Act;

128 (ii) an osteopathic physician and surgeon under Chapter 68, Utah Osteopathic Medical  
129 Practice Act;

130 (iii) a physician assistant under Chapter 70a, Physician Assistant Act;

131 (iv) a nurse practitioner under Chapter 31b, Nurse Practice Act; or

132 (v) an optometrist under Chapter 16a, Utah Optometry Practice Act, if the optometrist  
133 is acting within the scope of practice for an optometrist; and

134 (b) licensed by the division under the Pharmacy Practice Act to engage in the practice  
135 of a dispensing medical practitioner.

136 (24) "Dispensing medical practitioner clinic pharmacy" means a closed-door pharmacy  
137 located within a licensed dispensing medical practitioner's place of practice.

138 (25) "Distribute" means to deliver a drug or device other than by administering or  
139 dispensing.

140 (26) (a) "Drug" means:

141 (i) a substance recognized in the official United States Pharmacopoeia, official  
142 Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any  
143 supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or  
144 prevention of disease in humans or animals;

145 (ii) a substance that is required by any applicable federal or state law or rule to be  
146 dispensed by prescription only or is restricted to administration by practitioners only;

147 (iii) a substance other than food intended to affect the structure or any function of the  
148 body of humans or other animals; and

149 (iv) substances intended for use as a component of any substance specified in  
150 Subsections (26)(a)(i), (ii), (iii), and (iv).

151 (b) "Drug" does not include dietary supplements.

- 152 (27) "Drug regimen review" includes the following activities:  
153 (a) evaluation of the prescription drug order and patient record for:  
154 (i) known allergies;  
155 (ii) rational therapy-contraindications;  
156 (iii) reasonable dose and route of administration; and  
157 (iv) reasonable directions for use;  
158 (b) evaluation of the prescription drug order and patient record for duplication of  
159 therapy;  
160 (c) evaluation of the prescription drug order and patient record for the following  
161 interactions:  
162 (i) drug-drug;  
163 (ii) drug-food;  
164 (iii) drug-disease; and  
165 (iv) adverse drug reactions; and  
166 (d) evaluation of the prescription drug order and patient record for proper utilization,  
167 including over- or under-utilization, and optimum therapeutic outcomes.  
168 (28) "Drug sample" means a prescription drug packaged in small quantities consistent  
169 with limited dosage therapy of the particular drug, which is marked "sample", is not intended to  
170 be sold, and is intended to be provided to practitioners for the immediate needs of patients for  
171 trial purposes or to provide the drug to the patient until a prescription can be filled by the  
172 patient.  
173 (29) "Electronic signature" means a trusted, verifiable, and secure electronic sound,  
174 symbol, or process attached to or logically associated with a record and executed or adopted by  
175 a person with the intent to sign the record.  
176 (30) "Electronic transmission" means transmission of information in electronic form or  
177 the transmission of the exact visual image of a document by way of electronic equipment.  
178 (31) "Hospital pharmacy" means a pharmacy providing pharmaceutical care to  
179 inpatients of a general acute hospital or specialty hospital licensed by the Department of Health  
180 under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act.  
181 (32) "Legend drug" has the same meaning as prescription drug.  
182 (33) "Licensed pharmacy technician" means an individual licensed with the division,

183 that may, under the supervision of a pharmacist, perform the activities involved in the  
184 technician practice of pharmacy.

185 (34) "Manufacturer" means a person or business physically located in Utah licensed to  
186 be engaged in the manufacturing of drugs or devices.

187 (35) (a) "Manufacturing" means:

188 (i) the production, preparation, propagation, conversion, or processing of a drug or  
189 device, either directly or indirectly, by extraction from substances of natural origin or  
190 independently by means of chemical or biological synthesis, or by a combination of extraction  
191 and chemical synthesis, and includes any packaging or repackaging of the substance or labeling  
192 or relabeling of its container; and

193 (ii) the promotion and marketing of such drugs or devices.

194 (b) "Manufacturing" includes the preparation and promotion of commercially available  
195 products from bulk compounds for resale by pharmacies, practitioners, or other persons.

196 (c) "Manufacturing" does not include the preparation or compounding of a drug by a  
197 pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation,  
198 compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical  
199 analysis.

200 (36) "Medical order" means a lawful order of a practitioner which may include a  
201 prescription drug order.

202 (37) "Medication profile" or "profile" means a record system maintained as to drugs or  
203 devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to analyze  
204 the profile to provide pharmaceutical care.

205 (38) "Misbranded drug or device" means a drug or device considered misbranded under  
206 21 U.S.C. Sec. 352 (2003).

207 (39) (a) "Nonprescription drug" means a drug which:

208 (i) may be sold without a prescription; and

209 (ii) is labeled for use by the consumer in accordance with federal law.

210 (b) "Nonprescription drug" includes homeopathic remedies.

211 (40) "Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a  
212 person in Utah.

213 (41) "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service.

214 (42) "Out-of-state mail service pharmacy" means a pharmaceutical facility located  
215 outside the state that is licensed and in good standing in another state, that:

216 (a) ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in  
217 this state pursuant to a lawfully issued prescription;

218 (b) provides information to a patient in this state on drugs or devices which may  
219 include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses;  
220 or

221 (c) counsels pharmacy patients residing in this state concerning adverse and therapeutic  
222 effects of drugs.

223 (43) "Patient counseling" means the written and oral communication by the pharmacist  
224 or pharmacy intern of information, to the patient or caregiver, in order to ensure proper use of  
225 drugs, devices, and dietary supplements.

226 (44) "Pharmaceutical administration facility" means a facility, agency, or institution in  
227 which:

228 (a) prescription drugs or devices are held, stored, or are otherwise under the control of  
229 the facility or agency for administration to patients of that facility or agency;

230 (b) prescription drugs are dispensed to the facility or agency by a licensed pharmacist  
231 or pharmacy intern with whom the facility has established a prescription drug supervising  
232 relationship under which the pharmacist or pharmacy intern provides counseling to the facility  
233 or agency staff as required, and oversees drug control, accounting, and destruction; and

234 (c) prescription drugs are professionally administered in accordance with the order of a  
235 practitioner by an employee or agent of the facility or agency.

236 (45) (a) "Pharmaceutical care" means carrying out the following in collaboration with a  
237 prescribing practitioner, and in accordance with division rule:

238 (i) designing, implementing, and monitoring a therapeutic drug plan intended to  
239 achieve favorable outcomes related to a specific patient for the purpose of curing or preventing  
240 the patient's disease;

241 (ii) eliminating or reducing a patient's symptoms; or

242 (iii) arresting or slowing a disease process.

243 (b) "Pharmaceutical care" does not include prescribing of drugs without consent of a  
244 prescribing practitioner.



245 (46) "Pharmaceutical facility" means a business engaged in the dispensing, delivering,  
246 distributing, manufacturing, or wholesaling of prescription drugs or devices within or into this  
247 state.

248 (47) (a) "Pharmaceutical wholesaler or distributor" means a pharmaceutical facility  
249 engaged in the business of wholesale vending or selling of a prescription drug or device to  
250 other than a consumer or user of the prescription drug or device that the pharmaceutical facility  
251 has not produced, manufactured, compounded, or dispensed.

252 (b) "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical  
253 facility carrying out the following business activities:

254 (i) intracompany sales;

255 (ii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,  
256 purchase, or trade a prescription drug or device, if the activity is carried out between one or  
257 more of the following entities under common ownership or common administrative control, as  
258 defined by division rule:

259 (A) hospitals;

260 (B) pharmacies;

261 (C) chain pharmacy warehouses, as defined by division rule; or

262 (D) other health care entities, as defined by division rule;

263 (iii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,  
264 purchase, or trade a prescription drug or device, for emergency medical reasons, including  
265 supplying another pharmaceutical facility with a limited quantity of a drug, if:

266 (A) the facility is unable to obtain the drug through a normal distribution channel in  
267 sufficient time to eliminate the risk of harm to a patient that would result from a delay in  
268 obtaining the drug; and

269 (B) the quantity of the drug does not exceed an amount reasonably required for  
270 immediate dispensing to eliminate the risk of harm;

271 (iv) the distribution of a prescription drug or device as a sample by representatives of a  
272 manufacturer; and

273 (v) the distribution of prescription drugs, if:

274 (A) the facility's total distribution-related sales of prescription drugs does not exceed  
275 5% of the facility's total prescription drug sales; and

276 (B) the distribution otherwise complies with 21 C.F.R. Sec. 1307.11.

277 (48) "Pharmacist" means an individual licensed by this state to engage in the practice  
278 of pharmacy.

279 (49) "Pharmacist-in-charge" means a pharmacist currently licensed in good standing  
280 who accepts responsibility for the operation of a pharmacy in conformance with all laws and  
281 rules pertinent to the practice of pharmacy and the distribution of drugs, and who is personally  
282 in full and actual charge of the pharmacy and all personnel.

283 (50) "Pharmacist preceptor" means a licensed pharmacist in good standing with one or  
284 more years of licensed experience. The preceptor serves as a teacher, example of professional  
285 conduct, and supervisor of interns in the professional practice of pharmacy.

286 (51) "Pharmacy" means any place where:

287 (a) drugs are dispensed;

288 (b) pharmaceutical care is provided;

289 (c) drugs are processed or handled for eventual use by a patient; or

290 (d) drugs are used for the purpose of analysis or research.

291 (52) "Pharmacy benefits manager or coordinator" means a person or entity that  
292 provides a pharmacy [~~benefit~~] benefits management [~~services~~] service as defined in Section  
293 [49-20-502](#) on behalf of a self-insured employer, insurance company, health maintenance  
294 organization, or other plan sponsor, as defined by rule.

295 (53) "Pharmacy intern" means an individual licensed by this state to engage in practice  
296 as a pharmacy intern.

297 (54) "Pharmacy technician training program" means an approved technician training  
298 program providing education for pharmacy technicians.

299 (55) (a) "Practice as a dispensing medical practitioner" means the practice of pharmacy,  
300 specifically relating to the dispensing of a prescription drug in accordance with Part 8,  
301 Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, and  
302 division rule adopted after consultation with the Board of pharmacy and the governing boards  
303 of the practitioners described in Subsection (23)(a).

304 (b) "Practice as a dispensing medical practitioner" does not include:

305 (i) using a vending type of dispenser as defined by the division by administrative rule;

306 or

307 (ii) except as permitted by Section 58-17b-805, dispensing of a controlled substance as  
308 defined in Section 58-37-2.

309 (56) (a) "Practice as a licensed pharmacy technician" means engaging in practice as a  
310 pharmacy technician under the general supervision of a licensed pharmacist and in accordance  
311 with a scope of practice defined by division rule made in collaboration with the board.

312 (b) "Practice as a licensed pharmacy technician" does not include:

313 (i) performing a drug utilization review, prescription drug order clarification from a  
314 prescriber, final review of the prescription, dispensing of the drug, or counseling a patient with  
315 respect to a prescription drug;

316 (ii) except as permitted by rules made by the division in consultation with the board,  
317 final review of a prescribed drug prepared for dispensing;

318 (iii) counseling regarding nonprescription drugs and dietary supplements unless  
319 delegated by the supervising pharmacist; or

320 (iv) receiving new prescription drug orders when communicating telephonically or  
321 electronically unless the original information is recorded so the pharmacist may review the  
322 prescription drug order as transmitted.

323 (57) "Practice of pharmacy" includes the following:

324 (a) providing pharmaceutical care;

325 (b) collaborative pharmacy practice in accordance with a collaborative pharmacy  
326 practice agreement;

327 (c) compounding, packaging, labeling, dispensing, administering, and the coincident  
328 distribution of prescription drugs or devices, provided that the administration of a prescription  
329 drug or device is:

330 (i) pursuant to a lawful order of a practitioner when one is required by law; and

331 (ii) in accordance with written guidelines or protocols:

332 (A) established by the licensed facility in which the prescription drug or device is to be  
333 administered on an inpatient basis; or

334 (B) approved by the division, in collaboration with the board and the Physicians  
335 Licensing Board, created in Section 58-67-201, if the prescription drug or device is to be  
336 administered on an outpatient basis solely by a licensed pharmacist;

337 (d) participating in drug utilization review;

- 338 (e) ensuring proper and safe storage of drugs and devices;
- 339 (f) maintaining records of drugs and devices in accordance with state and federal law
- 340 and the standards and ethics of the profession;
- 341 (g) providing information on drugs or devices, which may include advice relating to
- 342 therapeutic values, potential hazards, and uses;
- 343 (h) providing drug product equivalents;
- 344 (i) supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy
- 345 technicians;
- 346 (j) providing patient counseling, including adverse and therapeutic effects of drugs;
- 347 (k) providing emergency refills as defined by rule;
- 348 (l) telepharmacy; [~~and~~]
- 349 (m) formulary management intervention[-]; and
- 350 (n) prescribing and dispensing a self-administered hormonal contraceptive in
- 351 accordance with Section [58-17b-626](#).

352 (58) "Practice of telepharmacy" means the practice of pharmacy through the use of

353 telecommunications and information technologies.

354 (59) "Practice of telepharmacy across state lines" means the practice of pharmacy

355 through the use of telecommunications and information technologies that occurs when the

356 patient is physically located within one jurisdiction and the pharmacist is located in another

357 jurisdiction.

358 (60) "Practitioner" means an individual currently licensed, registered, or otherwise

359 authorized by the appropriate jurisdiction to prescribe and administer drugs in the course of

360 professional practice.

361 (61) "Prescribe" means to issue a prescription:

- 362 (a) orally or in writing; or
- 363 (b) by telephone, facsimile transmission, computer, or other electronic means of
- 364 communication as defined by division rule.

365 (62) "Prescription" means an order issued:

- 366 (a) by a licensed practitioner in the course of that practitioner's professional practice or
- 367 by collaborative pharmacy practice agreement; and
- 368 (b) for a controlled substance or other prescription drug or device for use by a patient

369 or an animal.

370 (63) "Prescription device" means an instrument, apparatus, implement, machine,  
371 contrivance, implant, in vitro reagent, or other similar or related article, and any component  
372 part or accessory, which is required under federal or state law to be prescribed by a practitioner  
373 and dispensed by or through a person or entity licensed under this chapter or exempt from  
374 licensure under this chapter.

375 (64) "Prescription drug" means a drug that is required by federal or state law or rule to  
376 be dispensed only by prescription or is restricted to administration only by practitioners.

377 (65) "Repackage":

378 (a) means changing the container, wrapper, or labeling to further the distribution of a  
379 prescription drug; and

380 (b) does not include:

381 (i) Subsection (65)(a) when completed by the pharmacist responsible for dispensing the  
382 product to a patient; or

383 (ii) changing or altering a label as necessary for a dispensing practitioner under Part 8,  
384 Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, for  
385 dispensing a product to a patient.

386 (66) "Research using pharmaceuticals" means research:

387 (a) conducted in a research facility, as defined by division rule, that is associated with a  
388 university or college in the state accredited by the Northwest Commission on Colleges and  
389 Universities;

390 (b) requiring the use of a controlled substance, prescription drug, or prescription  
391 device;

392 (c) that uses the controlled substance, prescription drug, or prescription device in  
393 accordance with standard research protocols and techniques, including, if required, those  
394 approved by an institutional review committee; and

395 (d) that includes any documentation required for the conduct of the research and the  
396 handling of the controlled substance, prescription drug, or prescription device.

397 (67) "Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs  
398 and devices to the general public.

399 (68) (a) "Self-administered hormonal contraceptive" means a self-administered

400 hormonal contraceptive that is approved by the United States Food and Drug Administration to  
401 prevent pregnancy.

402 (b) "Self-administered hormonal contraceptive" includes an oral hormonal  
403 contraceptive, a hormonal vaginal ring, and a hormonal contraceptive patch.

404 (c) "Self-administered hormonal contraceptive" does not include any drug intended to  
405 induce an abortion, as that term is defined in Section 76-7-301.

406 [~~68~~] (69) "Self-audit" means an internal evaluation of a pharmacy to determine  
407 compliance with this chapter.

408 [~~69~~] (70) "Supervising pharmacist" means a pharmacist who is overseeing the  
409 operation of the pharmacy during a given day or shift.

410 [~~70~~] (71) "Supportive personnel" means unlicensed individuals who:

411 (a) may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed  
412 pharmacy technician in nonjudgmental duties not included in the definition of the practice of  
413 pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as  
414 those duties may be further defined by division rule adopted in collaboration with the board;  
415 and

416 (b) are supervised by a pharmacist in accordance with rules adopted by the division in  
417 collaboration with the board.

418 [~~71~~] (72) "Unlawful conduct" means the same as that term is defined in Sections  
419 58-1-501 and 58-17b-501.

420 [~~72~~] (73) "Unprofessional conduct" means the same as that term is defined in  
421 Sections 58-1-501 and 58-17b-502 and may be further defined by rule.

422 [~~73~~] (74) "Veterinary pharmaceutical facility" means a pharmaceutical facility that  
423 dispenses drugs intended for use by animals or for sale to veterinarians for the administration  
424 for animals.

425 Section 2. Section 58-17b-501 is amended to read:

426 **58-17b-501. Unlawful conduct.**

427 "Unlawful conduct" includes:

428 (1) knowingly preventing or refusing to permit an authorized agent of the division to  
429 conduct an inspection pursuant to Section 58-17b-103;

430 (2) failing to deliver the license, permit, or certificate to the division upon demand, if it

431 has been revoked, suspended, or refused;

432 (3) (a) using the title "pharmacist," "druggist," "pharmacy intern," "pharmacy  
433 technician," or a term having similar meaning, except by a person licensed as a pharmacist,  
434 pharmacy intern, or pharmacy technician; or

435 (b) conducting or transacting business under a name that contains, as part of that name,  
436 the words "drugstore," "pharmacy," "drugs," "medicine store," "medicines," "drug shop,"  
437 "apothecary," "prescriptions," or a term having a similar meaning, or in any manner  
438 advertising, otherwise describing, or referring to the place of the conducted business or  
439 profession, unless the place is a pharmacy issued a license by the division, except an  
440 establishment selling nonprescription drugs and supplies may display signs bearing the words  
441 "packaged drugs," "drug sundries," or "nonprescription drugs," and is not considered to be a  
442 pharmacy or drugstore by reason of the display;

443 (4) buying, selling, causing to be sold, or offering for sale, a drug or device that bears,  
444 or the package bears or originally did bear, the inscription "sample," "not for resale," "for  
445 investigational or experimental use only," or other similar words, except when a cost is  
446 incurred in the bona fide acquisition of an investigational or experimental drug;

447 (5) using to a person's own advantages or revealing to anyone other than the division,  
448 board, and its authorized representatives, or to the courts, when relevant to a judicial or  
449 administrative proceeding under this chapter, information acquired under authority of this  
450 chapter or concerning a method of process that is a trade secret;

451 (6) procuring or attempting to procure a drug or to have someone else procure or  
452 attempt to procure a drug:

453 (a) by fraud, deceit, misrepresentation, or subterfuge;

454 (b) by forgery or alteration of a prescription or a written order;

455 (c) by concealment of a material fact;

456 (d) by use of a false statement in a prescription, chart, order, or report; or

457 (e) by theft;

458 (7) filling, refilling, or advertising the filling or refilling of prescriptions for a  
459 consumer or patient residing in this state if the person is not licensed:

460 (a) under this chapter; or

461 (b) in the state from which he is dispensing;

- 462 (8) requiring an employed pharmacist, pharmacy intern, pharmacy technician, or  
463 authorized supportive personnel to engage in conduct in violation of this chapter;
- 464 (9) being in possession of a prescription drug for an unlawful purpose;
- 465 (10) dispensing a prescription drug to a person who does not have a prescription from a  
466 practitioner, except as permitted under Title 26, Chapter 55, Opiate Overdose Response Act, or  
467 Section 58-17b-626;
- 468 (11) dispensing a prescription drug to a person who the person dispensing the drug  
469 knows or should know is attempting to obtain drugs by fraud or misrepresentation;
- 470 ~~[(11)]~~ (12) selling, dispensing, distributing, or otherwise trafficking in prescription  
471 drugs when not licensed to do so or when not exempted from licensure; and
- 472 ~~[(12)]~~ (13) a person using a prescription drug or controlled substance that was not  
473 lawfully prescribed for the person by a practitioner.

474 Section 3. Section **58-17b-502** is amended to read:

475 **58-17b-502. Unprofessional conduct.**

476 "Unprofessional conduct" includes:

- 477 (1) willfully deceiving or attempting to deceive the division, the board, or their agents  
478 as to any relevant matter regarding compliance under this chapter;
- 479 (2) (a) except as provided in Subsection (2)(b):
- 480 (i) paying or offering rebates to practitioners or any other health care providers, or  
481 receiving or soliciting rebates from practitioners or any other health care provider; or
- 482 (ii) paying, offering, receiving, or soliciting compensation in the form of a commission,  
483 bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care  
484 provider, for the purpose of obtaining referrals.
- 485 (b) Subsection (2)(a) does not apply to:
- 486 (i) giving or receiving price discounts based on purchase volume;
- 487 (ii) passing along pharmaceutical manufacturer's rebates; or
- 488 (iii) providing compensation for services to a veterinarian.
- 489 (3) misbranding or adulteration of any drug or device or the sale, distribution, or  
490 dispensing of any outdated, misbranded, or adulterated drug or device;
- 491 (4) engaging in the sale or purchase of drugs or devices that are samples or packages  
492 bearing the inscription "sample" or "not for resale" or similar words or phrases;



493 (5) except as provided in Section [58-17b-503](#) or Part 9, Charitable Prescription Drug  
494 Recycling Act, accepting back and redistributing any unused drug, or a part of it, after it has  
495 left the premises of any pharmacy, unless the drug is in a unit pack, as defined in Section  
496 [58-17b-503](#), or the manufacturer's sealed container, as defined in rule;

497 (6) an act in violation of this chapter committed by a person for any form of  
498 compensation if the act is incidental to the person's professional activities, including the  
499 activities of a pharmacist, pharmacy intern, or pharmacy technician;

500 (7) violating [~~Federal Title II, P.L. 91, Controlled Substances Act,~~];

501 (a) the federal Controlled Substances Act, Title II, P.L. 91-513;

502 (b) Title 58, Chapter 37, Utah Controlled Substances Act[-]; or

503 (c) rules or regulations adopted under either act;

504 (8) requiring or permitting pharmacy interns or technicians to engage in activities  
505 outside the scope of practice for their respective license classifications, as defined in this  
506 chapter and division rules made in collaboration with the board, or beyond their scope of  
507 training and ability;

508 (9) administering:

509 (a) without appropriate training, as defined by rule;

510 (b) without a physician's order, when one is required by law; and

511 (c) in conflict with a practitioner's written guidelines or written protocol for  
512 administering;

513 (10) disclosing confidential patient information in violation of the provisions of the  
514 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat.  
515 1936, as amended, or other applicable law;

516 (11) engaging in the practice of pharmacy without a licensed pharmacist designated as  
517 the pharmacist-in-charge;

518 (12) failing to report to the division any adverse action taken by another licensing  
519 jurisdiction, government agency, law enforcement agency, or court for conduct that in  
520 substance would be considered unprofessional conduct under this section; ~~and~~

521 (13) as a pharmacist or pharmacy intern, compounding a prescription drug in a dosage  
522 form which is regularly and commonly available from a manufacturer in quantities and  
523 strengths prescribed by a practitioner[-]; and

524 (14) failing to act in accordance with Section 58-17b-626 when prescribing and  
525 dispensing a self-administered hormonal contraceptive.

526 Section 4. Section **58-17b-626** is enacted to read:

527 **58-17b-626. Authority to prescribe and dispense certain contraceptives.**

528 (1) (a) A pharmacist may prescribe and dispense a self-administered hormonal  
529 contraceptive if the pharmacist:

530 (i) has completed a course on the prescribing of contraceptives that has been approved  
531 by the board or the Accreditation Council for Pharmacy Education;

532 (ii) if more than two years has passed since the pharmacist has completed the course  
533 described in Subsection (1)(a)(i), has, within the last two years, completed a continuing  
534 education course on contraceptives that has been approved by the board;

535 (iii) submits a copy of the certificate of completion for the courses described in  
536 Subsections (1)(a)(i) and (ii) to the division;

537 (iv) notifies the division that the pharmacist intends to prescribe and dispense  
538 self-administered hormonal contraceptives under this section; and

539 (v) prescribes and dispenses self-administered hormonal contraceptives in accordance  
540 with this chapter.

541 (b) A pharmacist who currently prescribes and dispenses a self-administered hormonal  
542 contraceptive shall maintain the certificate of completion for courses taken to fulfill the  
543 requirements described in Subsections (1)(a)(i) and (ii) and make the certificates of completion  
544 available upon request.

545 (2) A pharmacist may not prescribe a self-administered hormonal contraceptive under  
546 this section to an individual who is under 18 years of age.

547 (3) For each new patient requesting a prescription for a self-administered hormonal  
548 contraceptive, and at least every 12 months for each returning patient requesting a  
549 self-administered hormonal contraceptive, a participating pharmacist shall:

550 (a) obtain a completed self-screening risk assessment questionnaire approved by the  
551 board;

552 (b) follow the procedure described in Subsection (4) to ensure that the patient does not  
553 have any contraindicating factors;

554 (c) prescribe a self-administered hormonal contraceptive, if clinically appropriate, or

555 refer the patient to a primary care or women's health care practitioner;  
556 (d) provide the patient with the documentation required in Subsection (5);  
557 (e) advise the patient to consult with a primary care or women's health care  
558 practitioner; and  
559 (f) document the encounter and maintain records in accordance with Subsection (7).  
560 (4) (a) Before prescribing contraceptive supplies to a patient, a pharmacist shall  
561 evaluate the patient's health and medical history to determine whether the patient:  
562 (i) has any contraindicating conditions, including uncontrolled hypertension;  
563 (ii) is pregnant;  
564 (iii) is taking any contraindicating medications; or  
565 (iv) is currently using any self-administered hormonal contraceptive.  
566 (b) A pharmacist shall use a standard procedures algorithm approved by the board as  
567 part of the patient assessment described in Subsection (4)(a).  
568 (c) If the results of the evaluation in Subsection (4)(a) indicate that it is unsafe to  
569 prescribe a self-administered hormonal contraceptive to a patient, the pharmacist:  
570 (i) may not prescribe a self-administered hormonal contraceptive to the patient; and  
571 (ii) shall refer the patient to a primary care or women's health care practitioner.  
572 (5) The pharmacist shall provide the patient with:  
573 (a) written information regarding:  
574 (i) the importance of seeing the patient's primary care practitioner or women's health  
575 care practitioner to obtain recommended tests and screening; and  
576 (ii) the effectiveness and availability of long-acting reversible contraceptives as an  
577 alternative to self-administered hormonal contraceptives; and  
578 (b) a copy of the record of the encounter that includes:  
579 (i) the patient's completed self-assessment tool; and  
580 (ii) the contraceptives prescribed and dispensed, or the basis for not prescribing and  
581 dispensing a contraceptive.  
582 (6) If a pharmacist prescribes a self-administered hormonal contraceptive to a patient,  
583 the pharmacist shall:  
584 (a) at minimum, counsel the patient on:  
585 (i) the appropriate administration and storage of the self-administered hormonal

586 contraceptive;

587 (ii) potential side effects and risks of the self-administered hormonal contraceptive;

588 (iii) the need for backup contraception;

589 (iv) when to seek emergency medical attention;

590 (v) the risk of contracting a sexually transmitted infection or disease, and ways to

591 reduce the risk of contraction; and

592 (vi) ways to contact the pharmacy with any follow-up questions; and

593 (b) dispense the self-administered hormonal contraceptive to the patient as soon as

594 practicable after the pharmacist issues the prescription.

595 (7) (a) The pharmacist shall maintain a record of an encounter described in this section,

596 including the written self-screening risk assessment questionnaire, for a minimum of five years

597 and in accordance with applicable state and federal law.

598 (b) A pharmacist may maintain the records described in Subsection (7)(a) in an

599 electronic health record maintained on the patient by the pharmacist.

600 (8) A pharmacist who prescribes a self-administered hormonal contraceptive to a

601 patient under this section may not continue to prescribe and dispense a self-administered

602 hormonal contraceptive to the patient more than three years after the date of the initial

603 prescription without evidence that the patient has consulted with a primary care or women's

604 health care practitioner during the preceding three years.

605 (9) (a) The board shall make rules in accordance with Title 63G, Chapter 3, Utah

606 Administrative Rulemaking Act, establishing:

607 (i) the self-screening risk assessment questionnaire described in Subsection (3)(a); and

608 (ii) a standard procedures algorithm, described in Subsection (4)(b), to evaluate the

609 safety of prescribing a self-administered hormonal contraceptive to a patient.

610 (b) The board may make rules in accordance with Title 63G, Chapter 3, Utah

611 Administrative Rulemaking Act, to:

612 (i) approve courses required under Subsections (1)(a)(i) and (ii) for a pharmacist who

613 prescribes self-administered hormonal contraceptives under this section; and

614 (ii) develop prescribing standards and practices consistent with the requirements of this

615 section.

616 (c) When making rules under this Subsection (9), the board shall seek

617 recommendations from the Department of Health and the Physicians Licensing Board.

618 (10) Nothing in this section shall be read to require a pharmacist to provide the services

619 described in this section.

---

---

**Legislative Review Note**  
**Office of Legislative Research and General Counsel**